1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Beyond Vaccines: CDC's ACIP To Look At Antibodies For Respiratory Syncytial Virus Prevention

 
• By Sue Sutter

New maternal/pediatric work group will consider recommendations for use of RSV vaccines and monoclonal antibodies targeting protection of children <18 years. With several products in the late-stage pipeline, group has begun reviewing RSV epidemiology and discussing cost-effectiveness.

Beyond infinity pool
CDC's Advisory Committee on Immunization Practices is looking beyond vaccines to prevent RSV. • Source: Alamy

Monoclonal antibodies in development to prevent respiratory syncytial virus (RSV) in children will not only have to satisfy US Food and Drug Administration requirements for product licensure, they will need to secure a recommendation for use from the Centers for Disease Control and Prevention panel that typically vets traditional vaccines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers